JCR Pharmaceuticals Co., Ltd. (4552) AI Stock Analysis

• Market Cap: ¥87.49B
• Dividend Yield: 2.71%
• Average Volume (3M): 578.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 7.15%
• EPS Growth: -454.41%
• Country: JP
• Employees: 934
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 18.51
• Shares Outstanding: 129,686,310
• 10 Day Avg. Volume: 668,090
• 30 Day Avg. Volume: 578,686
• PEG Ratio: 0.07
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 1.81
• P/FCF Ratio: -3.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ¥748.00 ▲(5.06% Upside)

The overall stock score is primarily influenced by strong technical analysis, indicating bullish momentum. However, significant financial challenges and a negative P/E ratio weigh down the score. The attractive dividend yield provides some support, but the company's financial health needs improvement to sustain long-term growth.

Positive Factors

Strong R&D Focus

A strong emphasis on R&D in rare diseases and regenerative medicine positions JCR Pharmaceuticals to innovate and potentially capture new market opportunities.

Revenue from Premium Products

Specialized products priced at a premium provide a stable revenue stream, supporting long-term financial health and enabling continued investment in innovation.

Collaborations and Partnerships

Strategic partnerships can enhance R&D capabilities, provide additional revenue through licensing, and support long-term growth through shared expertise and resources.

Negative Factors

Declining Profitability

Declining profitability and negative margins indicate operational inefficiencies, which could hinder long-term financial stability and growth prospects.

Rising Debt Levels

Increasing debt levels can strain financial flexibility and lead to higher interest obligations, potentially impacting the company's ability to invest in growth.

Negative Cash Flow

Negative cash flow indicates poor cash generation from operations, raising concerns about the company's ability to sustain operations and fund future growth without external financing.

JCR Pharmaceuticals Co., Ltd. Business Overview & Revenue Model

Company Description

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

How the Company Makes Money

JCR Pharmaceuticals generates revenue primarily through the sale of its biopharmaceutical products, including enzyme replacement therapies for rare diseases, which are often priced at a premium due to their specialized nature. The company also engages in collaborations and partnerships with other pharmaceutical companies and research institutions, which can provide additional revenue through licensing agreements, co-development projects, and milestone payments. Furthermore, government subsidies and grants for research into rare diseases can contribute to its funding, enhancing its financial stability and ability to invest in new product development.

JCR Pharmaceuticals Co., Ltd. Financial Statement Overview

Summary

JCR Pharmaceuticals Co., Ltd. faces significant financial challenges. The income statement shows declining profitability and revenue, with negative margins indicating operational inefficiencies. The balance sheet is stable but under pressure from increasing debt levels. Cash flow issues are apparent with negative operating and free cash flows, indicating liquidity constraints. Overall, the company needs to address revenue growth, cost management, and debt levels to improve its financial health.

Income Statement

The income statement reflects significant volatility. Gross profit margins were generally strong in past years but have suffered recently due to declining revenue and increased costs. The net profit margin has turned negative in the latest year, indicating operational challenges. Revenue growth has been inconsistent, with a notable decline in the most recent year. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a stable equity base, but with a concerning rise in total debt, increasing the debt-to-equity ratio. Return on equity has turned negative due to recent net losses. However, the equity ratio remains healthy, indicating a strong asset base relative to liabilities. The financial structure suggests potential risks if the current trend of increasing debt continues.

Cash Flow

The cash flow statement highlights challenges with a negative free cash flow and operating cash flow in the latest period. The operating cash flow to net income ratio shows poor cash generation from operations, suggesting inefficiencies. The free cash flow has decreased significantly, raising concerns about the company's ability to fund operations and growth without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	33.50B	33.07B	42.87B	34.34B	51.08B	30.09B
Gross Profit	21.86B	21.55B	31.25B	25.46B	40.62B	22.27B
EBITDA	-4.42B	-2.88B	10.53B	7.45B	21.39B	10.59B
Net Income	-5.50B	-4.76B	5.51B	3.77B	14.51B	6.89B
Balance Sheet
Total Assets	107.34B	104.86B	102.23B	94.94B	97.13B	73.78B
Cash, Cash Equivalents and Short-Term Investments	13.18B	13.20B	18.76B	13.28B	30.98B	26.26B
Total Debt	40.10B	38.10B	23.30B	22.80B	18.10B	18.10B
Total Liabilities	60.72B	57.42B	45.75B	42.52B	46.05B	35.23B
Stockholders Equity	46.26B	47.04B	56.18B	52.16B	50.88B	38.38B
Cash Flow
Free Cash Flow	0.00	-15.37B	7.22B	-14.06B	-2.04B	2.81B
Operating Cash Flow	0.00	-5.49B	9.31B	-5.50B	9.29B	10.34B
Investing Cash Flow	0.00	-9.87B	-2.69B	-15.00B	-3.25B	-3.29B
Financing Cash Flow	0.00	9.74B	-2.03B	1.95B	-2.18B	8.30B

JCR Pharmaceuticals Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 712.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4552, the sentiment is Positive. The current price of 712 is below the 20-day moving average (MA) of 720.85, above the 50-day MA of 688.92, and above the 200-day MA of 590.62, indicating a neutral trend. The MACD of 0.83 indicates Positive momentum. The RSI at 48.96 is Neutral, neither overbought nor oversold. The STOCH value of 48.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4552.

JCR Pharmaceuticals Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4534	73 Outperform	¥123.01B	19.08	5.11%	2.34%	4.35%	48.30%
4569	69 Neutral	¥84.17B	9.85	―	3.36%	11.65%	93.46%
4886	67 Neutral	¥55.91B	12.50	―	2.52%	5.44%	-20.33%
4552	58 Neutral	¥87.49B	-36.52	―	2.71%	7.15%	-454.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4565	40 Neutral	¥78.73B	-12.76	-9.05%	―	-1.96%	-64.18%

JCR Pharmaceuticals Co., Ltd. Corporate Events

JCR Pharmaceuticals Strikes Exclusive Japan Deal With Italfarmaco for DMD Drug Givinostat

JCR Pharmaceuticals and Italy’s Italfarmaco have signed an exclusive licensing agreement granting JCR the rights to develop and commercialize the Duchenne muscular dystrophy drug givinostat in Japan, where it is not yet approved despite authorizations in the US, EU and UK. JCR will handle local clinical development and regulatory submissions, while the deal also establishes a broader strategic collaboration to pursue additional rare disease therapies, potentially including future R&D partnerships and cross-licensing. The move strengthens JCR’s rare disease portfolio and positions it as a key player in bringing an important DMD treatment to the Japanese market, though the financial impact on its current fiscal year results is still under review.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen748.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

JCR Pharmaceuticals Reports Strong Financial Recovery in First Half of FY2025

JCR Pharmaceuticals reported a significant improvement in its financial performance for the six months ending September 30, 2025, with net sales increasing by 28.2% year-on-year. The company achieved a net profit attributable to owners of the parent of 1,710 million yen, a notable turnaround from the previous year’s loss. This positive financial outcome reflects the company’s strengthened market position and operational efficiency, potentially enhancing stakeholder confidence and supporting future growth initiatives.

The most recent analyst rating on (JP:4552) stock is a Hold with a Yen601.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.